High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
01 2019
Historique:
received: 18 05 2018
revised: 02 08 2018
accepted: 04 08 2018
pubmed: 20 8 2018
medline: 16 11 2019
entrez: 20 8 2018
Statut: ppublish

Résumé

Papillary renal cell carcinoma (PRCC) is currently divided in 2 subtypes. We reviewed a large cohort of PRCC and correlated subtype, morphological features and diagnostic marker expression with overall survival (OS) to uncover differences between the 2 subtypes. Three hundred seventy-six renal tumors initially diagnosed as PRCC with clinical and survival data were collected from the participating centers. Two hundred forty-six tumors were classified as PRCC1 (65.4%) and 130 as PRCC2 (34.6%) and graded according to the 2016 World Health Organization/International Society of Urological Pathology grading system. Morphological features (abundant cytoplasm, necrosis, fibrous stroma, foamy macrophages and psammoma bodies) were noted. Immunohistochemical stains (MIB1, p53, Racemase, EMA, CK7, CK20, E-Cadherin) were performed using tissue microarrays. χ

Identifiants

pubmed: 30121370
pii: S0046-8177(18)30311-3
doi: 10.1016/j.humpath.2018.08.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

212-223

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Iris Polifka (I)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany. Electronic address: iris.polifka@uk-erlangen.de.

Abbas Agaimy (A)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.

Edwin Herrmann (E)

Department of Urology, University Hospital Muenster, 48149 Muenster, Germany.

Verena Spath (V)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.

Lutz Trojan (L)

Department of Urology, University Hospital Göttingen, 37075 Göttingen, Germany.

Michael Stöckle (M)

Department of Urology and Pediatric Urology, University of Saarland (UKS), 66421 Homburg, Germany.

Frank Becker (F)

Department of Urology and Pediatric Urology, University of Saarland (UKS), 66421 Homburg, Germany.

Philipp Ströbel (P)

Department of Pathology, University Hospital Göttingen, 37075 Göttingen, Germany.

Christian Wülfing (C)

Department of Urology, University Hospital Muenster, 48149 Muenster, Germany.

Andres J Schrader (AJ)

Department of Urology, University of Marburg, 35037 Marburg, Germany.

Peter Barth (P)

Department of Urology, University of Marburg, 35037 Marburg, Germany.

Michael Staehler (M)

Department of Urology, University Hospital Munich, 81337 Munich, Germany.

Christian Stief (C)

Department of Urology, University Hospital Munich, 81337 Munich, Germany.

Markus Hohenfellner (M)

Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Stephan Macher-Göppinger (S)

Institute of Pathology, University Hospital Mainz, 55131 Mainz, Germany.

Bernd Wullich (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91058 Erlangen, Germany.

Joachim Noldus (J)

Department of Urology, Marien Hospital Herne, Ruhr University Bochum, 44625 Herne, Germany.

Walburgis Brenner (W)

Department of Urology, University of Mainz, 55131 Mainz, Germany.

Frederik C Roos (FC)

Department of Urology, University Hospital Frankfurt, 60590 Frankfurt/Main, Germany.

Bernhard Walter (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91058 Erlangen, Germany.

Wolfgang Otto (W)

Department of Urology, University of Regensburg, 93053 Regensburg, Germany.

Maximilian Burger (M)

Department of Urology, University of Regensburg, 93053 Regensburg, Germany.

Heinz Höfler (H)

Institute of Pathology, Technical University of Munich (TUM), 81675 Munich.

Axel Haferkamp (A)

Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Carol I Geppert (CI)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.

Christine Stöhr (C)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH